Introduction to Genomics in Hematologic Malignancy
Ce dossier présente un ensemble d'articles mettant en évidence le rôle de la génomique dans la prise en charge de différents types de cancers hématologiques (néoplasies myéloprolifératives, myélome multiple, lymphome non hodgkinien à tricholeucocytes, leucémies, ...)
The growing field of genomic medicine has had a profound impact on our understanding of malignancy. For many cancers, we are now in an era of precision medicine, where therapy is individualized based on genetic and molecular features of the tumor. In this special series issue of Journal of Clinical Oncology, we focus on the power of genomics in defining the biology of hematologic malignancies. Common themes emerge from the set of articles. Each hematologic malignancy discussed has complex genetics caused by the combinatorial diversity of somatic genetic mutations. However, many malignancies are associated with frequent disruption of a single biologic process, such as Janus kinase 2 signaling in myeloproliferative neoplasms, the mRNA spliceosome in myelodysplastic syndrome, and mitogen-activated protein kinase signaling in multiple myeloma. Clinical genetics offers the potential for improved disease classification, prognostication, identification of predictors of therapeutic response, and evaluation of the depth of disease remission. The articles in this issue, written by international authorities in the field, emphasize the translation of this increased genomic understanding to the clinic, with the practicing hematologist and oncologist in mind.
Journal of Clinical Oncology , résumé, 2016